Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Nicholson

Urology Lubbock, TX Medical Doctor

NPI 1376541490 CMS profile 152480

3612 23Rd St, Lubbock, TX 79410

Open in the dashboard

General payments

$6,764

336 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Nicholson of Lubbock, TX is reported in the CMS Open Payments database as having received $6,764 across 336 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,361 55
2024 General $1,433 64
2023 General $1,078 58
2022 General $1,187 64
2021 General $808 44
2020 General $275 16
2019 General $621 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Nicholson
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Brian Nicholson were reported at $1,361. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Brian Nicholson Urology median Middle half National median
2019 $621 $480 $147–$1,201 $163
2020 $275 $246 $87–$645 $114
2021 $808 $358 $111–$1,000 $132
2022 $1,187 $476 $143–$1,263 $149
2023 $1,078 $560 $168–$1,461 $160
2024 $1,433 $563 $170–$1,464 $164
2025 $1,361 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Astellas Pharma US Inc $1,527 71 payments
  2. Boston Scientific Corporation $1,218 61 payments
  3. Janssen Biotech, Inc. $715 43 payments
  4. Sumitomo Pharma America, Inc. $579 28 payments
  5. Pfizer Inc. $470 28 payments
  6. Coloplast Corp $334 17 payments
  7. AbbVie, Inc. $262 11 payments
  8. PROCEPT BioRobotics Corporation $186 6 payments
  9. Urogen Pharma, Inc. $118 6 payments
  10. ConvaTec Inc. $101 3 payments
  11. Other $1,255 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,402 332 payments
  2. Education $362 4 payments
Products named General payments · program years 2019–2025
  1. XTANDI $1,116 66 payments
  2. MYRBETRIQ $891 51 payments
  3. ERLEADA $715 43 payments
  4. GEMTESA $622 30 payments
  5. AMS 700 $439 17 payments
  6. ORGOVYX $406 24 payments
  7. TALZENNA $178 10 payments
  8. AQUABEAM ROBOTIC SYSTEM $125 4 payments
  9. AMS 800 Artificial Urinary Sphincter $122 7 payments
  10. BOTOX $121 5 payments
  11. Other $2,485 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

3,261

Median for Urology: 1,053

Drug cost

$911,219

Median for Urology: $101,464

Branded share of claims

38.3%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 45 $616,894
Myrbetriq Mirabegron Brand 220 $206,146
Mirabegron Er Mirabegron Brand 39 $23,981
Oxybutynin Chloride Er Oxybutynin Chloride Brand 534 $14,088
Tamsulosin Hcl Generic 819 $13,189
Finasteride Generic 801 $11,300
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 176 $8,412
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 47 $2,686
Trimethoprim Generic 21 $2,414
Potassium Citrate Er Potassium Citrate Brand 37 $2,033

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$204,870

Of which drugs: $28,593

Medicare patients

668

Average age 75

Services billed

26,801

191 women, 477 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 41%
Diabetes 36%
Cancer 30%
Chronic kidney disease 29%
Atrial fibrillation 22%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 20 174 $23,849
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 13 32 $58

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ERLEADA
  • Janssen Biotech, Inc. $209
$209 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $204
$204 — —
XTANDI
  • Astellas Pharma US Inc $81
  • PFIZER INC. $32
$113 45 —
JELMYTO
  • UROGEN PHARMA, INC. $69
$69 — —
MYRBETRIQ
  • Astellas Pharma US Inc $67
$67 220 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

336 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record